Brief: Wockhardt Announces Successful Initiation Of Global Phase 3 Clinical Study Of Novel Antibiotic
16/08/2022 03:23
Aug 16 (Reuters) - Wockhardt Ltd WCKH.NS :
* WOCKHARDT LTD - SUCCESSFUL INITIATION OF GLOBAL PHASE 3 CLINICAL STUDY OF ITS NOVEL
ANTIBIOTIC
Source text for Eikon: ID:nBSE3GCq9l
Further company coverage: WCKH.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wockhardt
See all newsBrief: Wockhardt Says Customs Authority Imposes 50 Million Rupees Penalty And 100 Million Rupees Redemption Fine On Co
Brief: Wockhardt Limited June-Quarter Consol Net Profit 1.06 Billion Rupees
India's Wockhardt gains after marketing authorization for antibiotic ZAYNICH
Brief: Wockhardt Says Indian Drug Regulator Grants Marketing Authorization To Co's Zaynich
India's Wockhardt hits 7‑month high after swinging to profit in fourth quarter